ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu

Open source

DOI: 10.1200/po-24-00818
Published: 2025-06
Container: JCO Precision Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/po-24-00818,
  title = {ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib},
  author = {Jonathan W. Riess and Adrianus J. de Langen and Santiago Ponce and Sarah B. Goldberg and Zofia Piotrowska and Jonathan W. Goldman and Xiuning Le and Byoung Chul Cho and Yasuto Yoneshima and Helen Ambrose and Riccardo Cavazzina and Kwan Ho Tang and James Lau and Helena A. Yu},
  year = {2025},
  journal = {JCO Precision Oncology},
  doi = {10.1200/po-24-00818},
  url = {https://doi.org/10.1200/po-24-00818}
}

RIS

TY  - JOUR
TI  - ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
AU  - Jonathan W. Riess
AU  - Adrianus J. de Langen
AU  - Santiago Ponce
AU  - Sarah B. Goldberg
AU  - Zofia Piotrowska
AU  - Jonathan W. Goldman
AU  - Xiuning Le
AU  - Byoung Chul Cho
AU  - Yasuto Yoneshima
AU  - Helen Ambrose
AU  - Riccardo Cavazzina
AU  - Kwan Ho Tang
AU  - James Lau
AU  - Helena A. Yu
PY  - 2025
JO  - JCO Precision Oncology
DO  - 10.1200/po-24-00818
UR  - https://doi.org/10.1200/po-24-00818
ER  -

APA

Riess, J. W., Langen, A. J. D., Ponce, S., Goldberg, S. B., Piotrowska, Z., Goldman, J. W., Le, X., Cho, B. C., Yoneshima, Y., Ambrose, H., Cavazzina, R., Tang, K. H., Lau, J., & Yu, H. A. (2025). ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology. https://doi.org/10.1200/po-24-00818

Source records

crossref · retrieved 2026-09-26T13:58:19.343Z